Avacta Group “promising evaluation of the Affimer reagents in Integumen’s sensor systems”

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has noted the update by Integumen plc (LON:SKIN) provided today regarding their ongoing development of Affimer-based sensors for the coronavirus in waste water and in human breath.

 Dr Alastair Smith, Chief Executive of Avacta Group commented:

“I am very pleased to learn of the promising evaluation of the Affimer reagents in Integumen’s sensor systems. Once detailed validation of the sensors has been carried out using SARS-COV-2 virus samples at the University of Aberdeen, and we have reviewed those data, Avacta will provide a further update to the market.” 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

Avacta plc notice regarding publication error

Regarding a recent aggregated news article published earlier today, which has since been taken down, this was an error on the DirectorsTalk part linking to old news. This was nothing to do with Avacta Plc. The source of

Avacta Group Plc

Avacta inks radiopharma deal with POINT Biopharma

UK-based Avacta Group (AIM: AVCT) has entered into a license agreement with Canadian firm POINT Biopharma to provide access to Avacta’s pre|CISION technology for the development of tumor-activated radiopharmaceuticals.  The radiopharmaceutical market is expected to grow to $15

Avacta Group Plc

Avacta signs new cancer therapy deal

Avacta Group, the developer of innovative cancer therapies, has entered into a license agreement with Point Biopharma to provide access to Avacta’s technology for the development of tumour-activated radiopharmaceuticals. Radiopharmaceutical therapy is now seen as a safe and